Skip to content

Minoxidil 5 mg oral versus Minoxidil 5 mg sublingual for treating Male Pattern Baldness

Minoxidil 5 mg oral versus Minoxidil 5 mg sublingual for the treatment of Male Androgenetic Alopecia: randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-7wsgdm8
Enrollment
Unknown
Registered
2023-04-19
Start date
2023-06-15
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic alopecia

Interventions

A randomized, paired, double-blind (patients and principal investigator – BDS), parallel, monocentric clinical trial will be conducted with a 24-week longitudinal follow-up.After signing the consent f
the expected benefits
the guarantee of clarifications, before and during the course of the research (on any aspect of the process)
the freedom to refuse to participate or withdraw your consent, at any stage of the research, without any penalty and without prejudice
the guarantee of secrecy and privacy regarding the confidential data involved Standard digital photographs will be taken (frontal, vertex and parietal regions at 45° and 90°), trichoscopic photo (in t

Sponsors

Clinica Sanabria Transplante e Restauração Capilar
Lead Sponsor
Clinica Sanabria Transplante e Restauração Capilar
Collaborator

Eligibility

Sex/Gender
Male
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Male patients; age between 18 and 55 years; diagnosed with Androgenetic Alopecia classified on the Norwood Hamilton scale in 3V, 4V or 5V; clarified and agreeing to participate in the research, during consultations carried out at Clínica Sanabria

Exclusion criteria

Exclusion criteria: Patients who underwent previous treatment for hair loss in the last 4 months; hypertensive; heart disease; kidney disease; patients with other causes of hair loss or scalp dermatoses

Design outcomes

Primary

MeasureTime frame
Expect to find an increase in the number of hairs in the regions studied after intervention with medication. This analysis will be performed using the following techniques. Trichoscopic photo will be taken in the vertex region using FotoFinder equipment. This same area (1 cm²) will be shaved, leaving hairs 1 mm long (for counting and hair thickness evaluation) and will be tattooed at two points (north and south) with red ink to ensure reproducibility of the evaluation. White hair will be dyed black to facilitate evaluation. These same parameters will be reassessed in an outpatient consultation in the 24th week of treatmentleaving hairs 1 mm long (for counting and hair thickness evaluation) and will be tattooed at two points (north and south) with red ink to ensure reproducibility of the evaluation. White hair will be dyed black to facilitate evaluation. These same parameters will be reassessed in an outpatient consultation in the 24th week of treatment. With the help of ImageJ® software, a total count and evaluation of the average thickness of the hairs in the region will be performed before the start of treatment and after 24 weeks. Wires thicker than 0.04 mm will be considered terminals.;It is expected to find an increase in the diameter of hair strands in the regions studied after intervention with medication. This analysis will be performed using the following techniques. With the help of ImageJ® software, a total count and evaluation of the average thickness of the hairs in the region will be performed before the start of treatment and after 24 weeks. Wires thicker than 0.04 mm will be considered terminals. nThese same parameters will be reassessed in an outpatient consultation in the 24th week of treatment

Secondary

MeasureTime frame
Secondary outcomes are not expected

Countries

Brazil

Contacts

Public ContactBaltazar Sanabria

Clinica Sanabria Transplante e Restauração Capilar

sanabriabaltazar@gmail.com+556732043445

Outcome results

None listed

Source: REBEC (via WHO ICTRP)